pax logo.png
PaxMedica Holds Meeting of Scientific Advisory Board
20 mars 2023 08h00 HE | PaxMedica, Inc.
Board Includes Several Key Opinion Leaders on Autism Spectrum Disorder in U.S. TARRYTOWN, NY, March 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical...
Affimed Logo.jpg
Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for Cancer Research
14 mars 2023 16h30 HE | Affimed N.V.
An oral presentation on the safety and efficacy from the AFM13 phase 2 monotherapy clinical study (“REDIRECT”) in patients with CD30-positive relapsed or refractory (R/R) peripheral T-cell lymphoma...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering
14 mars 2023 08h30 HE | Adamis Pharmaceuticals Corporation
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...
Cytovance_HepaLink_Digtial_032017.jpg
Cytovance Biologics and Phenotypeca Collaborate to Enhance Saccharomyces cerevisiae Strain Development for Microbial Biomanufacturing
11 mars 2023 07h00 HE | Cytovance Biologics
OKLAHOMA CITY, March 11, 2023 (GLOBE NEWSWIRE) -- Cytovance Biologics, Inc. (Cytovance Biologics), a biopharmaceutical contract development and manufacturing organization (CDMO), and Phenotypeca...
logo color s and clearside.jpg
Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
09 mars 2023 16h05 HE | Clearside Biomedical, Inc.
- Initiation of Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected in Q2 2023 - - Medical Meeting Presentations Highlight Significant Potential of CLS-AX Based on Positive OASIS Phase 1/2a Safety...
MicrosoftTeams-image (5).png
Clinical Trials Support Services Market Value to Reach US$ 48.5 Bn by 2033, as per TMR Report
08 mars 2023 12h00 HE | Transparency Market Research
Wilmington, Delaware, United States, March 08, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. – The global Clinical Trials Support Services Market is projected to expand at a CAGR of...
MBX Logos FINAL FULL.jpg
MBX Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
07 mars 2023 08h00 HE | MBX Biosciences, Inc.
CARMEL, Ind., March 07, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
ibn-iw-globe-2.png
IBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research Institutes
03 mars 2023 14h07 HE | InvestorBrandNetwork (IBN)
LOS ANGELES, March 03, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN, a multifaceted financial news and publishing company for private and public entities, today announces that Amir Reichman, CEO...
Syneos Health_rgb_r.jpg
Syneos Health Reports Fourth Quarter and Full Year 2022 Results
16 févr. 2023 06h03 HE | Syneos Health, Inc.
Revenue for the fourth quarter of $1,359.9 million decreased 1.0% on a reported basis and increased 1.7% on a constant currency basis year-over-year.Clinical Solutions net new business awards and...
pax logo.png
PaxMedica Releases 2022 Shareholder Letter
15 févr. 2023 07h30 HE | PaxMedica, Inc.
Company Anticipates Multiple Milestones in Next 12-24 Months TARRYTOWN, NY, Feb. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage...